Development of stable isosteres of dihydrofolate reductase inhibitors as antibact

作为抗菌剂的二氢叶酸还原酶抑制剂的稳定等排体的开发

基本信息

  • 批准号:
    8591361
  • 负责人:
  • 金额:
    $ 28.78万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-07-01 至 2014-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: Antibiotic resistance among common bacterial pathogens is a serious public health problem as it compromises our ability to treat infectious disease. The resistance problem is compounded by the relative lack of discovery of new antibiotics, especially those with novel mechanisms of action. Over the past several years Promiliad Biopharma has been developing new inhibitors that target the enzyme dihydrofolate reductase as a method of treatment for pathogenic bacteria, fungi and protozoa. Through our efforts and those of our collaborators, largely funded by STTR grants, we have discovered a class of antifolates characterized by a 2, 4- diaminopyrimidine and a biaryl domain linked through a three-atom propargyl bridge. This class of molecules is an important lead in the discovery of a new treatment for infectious disease. The current class of compounds, while potent antibacterial agents with activity against antibiotic resistant pathogens, currently lack sufficient metabolic stability. These compounds have short in vivo (and in vitro) half-lives which make progression to lead compound status somewhat difficult. We have found that by substituting a key fragment of the structure with a non-metabolizable bioisostere we can retain potency against a range of Gram positive pathogens while greatly improving selectivity and metabolic half-life. The goal of this project is o design, synthesize and assay additional bioisosteric analogs which display similar or better improvements in potency, metabolism and physical properties. Our goal in this Phase I application is to obtain a clear lead candidate. A Phase II project continuing from this work would then conduct IND-enabling experiments with the clear goal of filing an IND application.
产品说明: 常见细菌病原体的抗生素耐药性是一个严重的公共卫生问题,因为它损害了我们治疗传染病的能力。由于相对缺乏新抗生素的发现,特别是那些具有新作用机制的抗生素,使耐药性问题更加复杂。在过去的几年里,Promiliad Bioprotima一直在开发针对二氢叶酸还原酶的新抑制剂,作为治疗病原菌,真菌和原生动物的方法。通过我们和我们的合作者的努力,主要由STTR赠款,我们发现了一类抗叶酸剂,其特征在于通过三原子炔丙基桥连接的2,4-二氨基嘧啶和联芳基结构域。这类分子是发现传染病新疗法的重要先导。目前这类化合物虽然具有针对抗生素耐药病原体的活性,但目前缺乏足够的代谢稳定性。这些化合物具有短的体内(和体外)半衰期,这使得进展到先导化合物状态有些困难。我们已经发现,通过用不可代谢的生物电子等排体取代结构的关键片段,我们可以保留针对一系列革兰氏阳性病原体的效力,同时大大提高选择性和代谢半衰期。本项目的目标是设计、合成和测定其他生物电子等排类似物,这些类似物在效力、代谢和物理性质方面表现出类似或更好的改善。我们在第一阶段申请中的目标是获得一个明确的领先候选人。第二阶段的项目将继续从这项工作,然后进行IND使能实验与提交IND申请的明确目标。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Nigel D PRIESTLEY其他文献

Nigel D PRIESTLEY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Nigel D PRIESTLEY', 18)}}的其他基金

Novel antibacterial agents derived from natural products
源自天然产物的新型抗菌剂
  • 批准号:
    9906163
  • 财政年份:
    2016
  • 资助金额:
    $ 28.78万
  • 项目类别:
Novel antibacterial agents derived from natural products
源自天然产物的新型抗菌剂
  • 批准号:
    9046851
  • 财政年份:
    2016
  • 资助金额:
    $ 28.78万
  • 项目类别:
Non-nucleoside inhibitors of DNA methyl transferase I
DNA 甲基转移酶 I 非核苷抑制剂
  • 批准号:
    8574469
  • 财政年份:
    2013
  • 资助金额:
    $ 28.78万
  • 项目类别:
Isoindolinones as Antimicrobial Agents
作为抗菌剂的异吲哚啉酮
  • 批准号:
    7483514
  • 财政年份:
    2008
  • 资助金额:
    $ 28.78万
  • 项目类别:
BIO-ENGINEERING OF COMPOUNDS ACTIVE AGAINST MDR CANCER
有效对抗耐多药癌症的化合物的生物工程
  • 批准号:
    6376679
  • 财政年份:
    1998
  • 资助金额:
    $ 28.78万
  • 项目类别:
BIO-ENGINEERING OF COMPOUNDS ACTIVE AGAINST MDR CANCER
有效对抗耐多药癌症的化合物的生物工程
  • 批准号:
    6765788
  • 财政年份:
    1998
  • 资助金额:
    $ 28.78万
  • 项目类别:
BIO-ENGINEERING OF COMPOUNDS ACTIVE AGAINST MDR CANCER
有效对抗耐多药癌症的化合物的生物工程
  • 批准号:
    6141338
  • 财政年份:
    1998
  • 资助金额:
    $ 28.78万
  • 项目类别:
BIO-ENGINEERING OF COMPOUNDS ACTIVE AGAINST MDR CANCER
有效对抗耐多药癌症的化合物的生物工程
  • 批准号:
    2896408
  • 财政年份:
    1998
  • 资助金额:
    $ 28.78万
  • 项目类别:
BIO-ENGINEERING OF COMPOUNDS ACTIVE AGAINST MDR CANCER
有效对抗耐多药癌症的化合物的生物工程
  • 批准号:
    6260415
  • 财政年份:
    1998
  • 资助金额:
    $ 28.78万
  • 项目类别:
BIO-ENGINEERING OF COMPOUNDS ACTIVE AGAINST MDR CANCER
有效对抗耐多药癌症的化合物的生物工程
  • 批准号:
    6684778
  • 财政年份:
    1998
  • 资助金额:
    $ 28.78万
  • 项目类别:

相似海外基金

The effects of antibiotics to the transfer frequency of the antibiotic resistance genes and the evolution of high-level resistance.
抗生素对抗生素抗性基因转移频率和高水平抗性进化的影响。
  • 批准号:
    22K05790
  • 财政年份:
    2022
  • 资助金额:
    $ 28.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
NEC05839 Chicken or the Egg: Is AMR in the Environment Driven by Dissemination of Antibiotics or Antibiotic Resistance Genes?
NEC05839 先有鸡还是先有蛋:环境中的抗菌素耐药性是由抗生素或抗生素抗性基因的传播驱动的吗?
  • 批准号:
    NE/N019687/2
  • 财政年份:
    2019
  • 资助金额:
    $ 28.78万
  • 项目类别:
    Research Grant
Combating Antibiotic Resistance to Aminoglycoside Antibiotics through Chemical Synthesis
通过化学合成对抗氨基糖苷类抗生素的耐药性
  • 批准号:
    392481159
  • 财政年份:
    2017
  • 资助金额:
    $ 28.78万
  • 项目类别:
    Research Fellowships
NEC05839 Chicken or the Egg: Is AMR in the Environment Driven by Dissemination of Antibiotics or Antibiotic Resistance Genes?
NEC05839 先有鸡还是先有蛋:环境中的抗菌素耐药性是由抗生素或抗生素抗性基因的传播驱动的吗?
  • 批准号:
    NE/N019687/1
  • 财政年份:
    2016
  • 资助金额:
    $ 28.78万
  • 项目类别:
    Research Grant
Chicken or the Egg: Is AMR in the Environment Driven by Dissemination of Antibiotics or Antibiotic Resistance Genes?
先有鸡还是先有蛋:环境中的抗菌素耐药性是由抗生素或抗生素抗性基因的传播驱动的吗?
  • 批准号:
    NE/N019857/1
  • 财政年份:
    2016
  • 资助金额:
    $ 28.78万
  • 项目类别:
    Research Grant
Chicken or the Egg: Is AMR in the Environment Driven by Dissemination of Antibiotics or Antibiotic Resistance Genes?
先有鸡还是先有蛋:环境中的抗菌素耐药性是由抗生素或抗生素抗性基因的传播驱动的吗?
  • 批准号:
    NE/N019717/1
  • 财政年份:
    2016
  • 资助金额:
    $ 28.78万
  • 项目类别:
    Research Grant
The SuDDICU study- A study of the impact of preventative antibiotics (SDD) on patient outcome and antibiotic resistance in the critically ill in intensive care
SuDDICU 研究 - 一项关于预防性抗生素 (SDD) 对重症监护病危患者的患者预后和抗生素耐药性影响的研究
  • 批准号:
    366555
  • 财政年份:
    2016
  • 资助金额:
    $ 28.78万
  • 项目类别:
    Operating Grants
The SuDDICU study- A study of the impact of preventative antibiotics (SDD) on patient outcome and antibiotic resistance in the critically ill in intensive care
SuDDICU 研究 - 一项关于预防性抗生素 (SDD) 对重症监护病危患者的患者预后和抗生素耐药性影响的研究
  • 批准号:
    361307
  • 财政年份:
    2016
  • 资助金额:
    $ 28.78万
  • 项目类别:
    Operating Grants
Contamination status of antibiotics and antibiotic resistance genes (ARGs) in tropical Asian aquatic environments with artificial and natural disturbance
人工和自然干扰下亚洲热带水生环境中抗生素和抗生素抗性基因(ARG)的污染状况
  • 批准号:
    25257402
  • 财政年份:
    2013
  • 资助金额:
    $ 28.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
RAPID: COLLABORATIVE RESEARCH: Fate and Transport of Antibiotics and Antibiotic Resistance Genes During Historic Colorado Flood
快速:合作研究:历史性科罗拉多洪水期间抗生素和抗生素抗性基因的命运和运输
  • 批准号:
    1402635
  • 财政年份:
    2013
  • 资助金额:
    $ 28.78万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了